# Phase 1/2 Multiple Myeloma trials recruiting: 78 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 78 trials in phase 1/2 for Multiple Myeloma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Multiple Myeloma trials: 78 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/multiple-myeloma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 78
- Recruiting or not yet: 78
- Read on: November 19, 2026

## Trials

The 25 newest of 78, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 3, 2026 | NCT07911748 | A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma. | Beijing Mabworks Biotech Co., Ltd. | Phase 1/2 | Not yet recruiting | Multiple Myeloma | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911748) |
| August 12, 2026 | NCT07760454 | A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma | UCARsgen Biotech Limited | Phase 1/2 | Recruiting | Relapsed/Refractory Multiple Myeloma | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760454) |
| July 15, 2026 | NCT07705074 | FAPI PET Imaging - An Exploratory Study | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis, Thyroid Cancer, Breast Cancer... | 770 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705074) |
| July 7, 2026 | NCT07687004 | Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification | Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | Not yet recruiting | Multiple Myeloma (MM) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07687004) |
| July 2, 2026 | NCT07681596 | A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma | AstraZeneca | Phase 1/2 | Recruiting | Relapsed or Refractory Multiple Myeloma | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681596) |
| May 29, 2026 | NCT07612787 | A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma | Centre Hospitalier Universitaire de Saint Etienne | Phase 1/2 | Not yet recruiting | Myeloma Multiple | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612787) |
| May 22, 2026 | NCT07601100 | Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma | Dana-Farber Cancer Institute | Phase 1/2 | Not yet recruiting | Newly Diagnosed Multiple Myeloma | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601100) |
| May 20, 2026 | NCT07600151 | Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma | Universitätsklinikum Hamburg-Eppendorf | Phase 1/2 | Not yet recruiting | Myeloma Multiple, Myeloma | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07600151) |
| April 13, 2026 | NCT07523555 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | Beijing Biotech | Phase 1/2 | Recruiting | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL... | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523555) |
| April 3, 2026 | NCT07510100 | Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | Nanjing IASO Biotechnology Co., Ltd. | Phase 1/2 | Not yet recruiting | Relapsed/Refractory Multiple Myeloma | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510100) |
| March 18, 2026 | NCT07479979 | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Relapse Multiple Myeloma, Refractory Multiple Myeloma | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07479979) |
| March 17, 2026 | NCT07477912 | Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | Phase 1/2 | Recruiting | Multiple Myeloma Refractory | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07477912) |
| March 11, 2026 | NCT07463807 | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib... | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Recurrent Multiple Myeloma, Refractory Multiple Myeloma | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07463807) |
| March 6, 2026 | NCT07455851 | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple... | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Relapsed Refractory Multiple Myeloma (RRMM) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455851) |
| March 6, 2026 | NCT07454187 | To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma | Hangzhou Sumgen Biotech Co., Ltd. | Phase 1/2 | Recruiting | Relapsed/Refractory Multiple Myeloma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07454187) |
| February 19, 2026 | NCT07421856 | Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. | Hebei Senlang Biotechnology Inc., Ltd. | Phase 1/2 | Not yet recruiting | Multiple Myeloma in Relapse, Multiple Myeloma Refractory | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421856) |
| February 13, 2026 | NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic), Prostate... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410494) |
| January 13, 2026 | NCT07336472 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | Fortvita Biologics (USA)Inc. | Phase 1/2 | Recruiting | Multiple Myeloma | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07336472) |
| October 7, 2025 | NCT07210047 | Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients | HuniLife Biotechnology, Inc. | Phase 1/2 | Recruiting | Multiple Myeloma Refractory | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07210047) |
| September 19, 2025 | NCT07181941 | Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple... | Fred Hutchinson Cancer Center | Phase 1/2 | Recruiting | Recurrent Multiple Myeloma, Refractory Multiple Myeloma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07181941) |
| September 11, 2025 | NCT07169500 | Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients | Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | Recruiting | Multiple Myeloma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07169500) |
| August 11, 2025 | NCT07116616 | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | ModernaTX, Inc. | Phase 1/2 | Recruiting | Relapsed or Refractory Multiple Myeloma | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07116616) |
| August 6, 2025 | NCT07107204 | A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies | Biotroy Therapeutics | Phase 1/2 | Not yet recruiting | Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma, Multiple Myeloma (MM) | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07107204) |
| August 1, 2025 | NCT07099391 | A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma | Memorial Sloan Kettering Cancer Center | Phase 1/2 | Recruiting | Multiple Myeloma | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07099391) |
| July 29, 2025 | NCT07090954 | A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Multiple Myeloma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07090954) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 4 |
| Xuzhou Medical University | 3 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 3 |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| Beijing Mabworks Biotech Co., Ltd. | 2 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 2 |
| Universitätsklinikum Hamburg-Eppendorf | 2 |
| Essen Biotech | 2 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 2 |
| The First Affiliated Hospital of Soochow University | 2 |
| M.D. Anderson Cancer Center | 2 |
| Shenzhen Geno-Immune Medical Institute | 2 |
| [ModernaTX, Inc.](https://specstream.ai/data/clinical-trials/company/modernatx-inc) | 1 |
| Indapta Therapeutics, INC. | 1 |
| Centre Hospitalier Universitaire de Saint Etienne | 1 |
| Fortvita Biologics (USA)Inc. | 1 |
| [Celgene](https://specstream.ai/data/clinical-trials/company/celgene) | 1 |
| National Cancer Institute (NCI) | 1 |
| [Hebei Senlang Biotechnology Inc., Ltd.](https://specstream.ai/data/clinical-trials/company/hebei-senlang-biotechnology-inc-ltd) | 1 |
| [Chengdu Zenitar Biomedical Technology Co., Ltd](https://specstream.ai/data/clinical-trials/company/chengdu-zenitar-biomedical-technology-co-ltd) | 1 |
| [Innovent Biologics (Suzhou) Co. Ltd.](https://specstream.ai/data/clinical-trials/company/innovent-biologics-suzhou-co-ltd) | 1 |
| Affiliated Hospital of Nantong University | 1 |
| Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 1 |
| Hangzhou Sumgen Biotech Co., Ltd. | 1 |
| Wake Forest University Health Sciences | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 33 |
| United States | 29 |
| United Kingdom | 12 |
| Spain | 11 |
| Australia | 10 |
| Germany | 9 |
| France | 7 |
| Japan | 7 |
| South Korea | 7 |
| Canada | 6 |
| Greece | 4 |
| Norway | 4 |
| Israel | 4 |
| Poland | 4 |
| Taiwan | 4 |
| Belgium | 3 |
| Italy | 3 |
| Sweden | 3 |
| Brazil | 3 |
| Singapore | 3 |
| Switzerland | 2 |
| Portugal | 1 |
| Belarus | 1 |
| Hungary | 1 |
| Romania | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Import and export companies in the United States](https://specstream.ai/data/businesses/import-and-export-companies/united-states)
- [Rubber and plastics manufacturers in the United States](https://specstream.ai/data/businesses/rubber-and-plastics-manufacturers/united-states)
- [Bakeries in the United States](https://specstream.ai/data/businesses/bakeries/united-states)
- [General hospitals in the United States](https://specstream.ai/data/businesses/general-hospitals/united-states)
- [Poke restaurants in the United States](https://specstream.ai/data/businesses/poke-restaurants/united-states)
- [Appellate practice law firms in the United States](https://specstream.ai/data/businesses/appellate-practice-law-firms/united-states)
